Jingsong Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jingsong Wang has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Lei Wang
Department of Urology Renmin Hospital of Wuhan University Wuhan Hubei China
2 shared publications - Qingyuan Zheng
Department of Urology, Renmin Hospital of Wuhan University, Wuhan, China
2 shared publications - Jiacheng Zhong
Renmin Hospital of Wuhan University, China
1 shared publication Jun Jian
Department of Urology Renmin Hospital of Wuhan University Wuhan Hubei China
1 shared publication- Jun Jian
Renmin Hospital of Wuhan University, China
1 shared publication - Panpan Jiao
Department of Urology Renmin Hospital of Wuhan University Wuhan Hubei China
1 shared publication
Latest Publications
- Open Access
- 8 January 2026
- Published by Wiley in Cancer Medicine
- Vol. 15 (1) , e71477
Machine Learning Integration Framework Constructs a Lactylation‐Associated Gene Signature to Improve Prognosis in Bladder Cancer
Background: Bladder cancer remains a significant challenge in oncology owing to its high recurrence rates and limited treatment options, particularly in cases of resistance to standard therapies. Aims: Our study aimed to pinpoint a lactylation‐associated gene signature capable of predicting prognosis and providing important theoretical support for drug development and precision therapy in bladder cancer patients. Materials and Methods: Leveraging RNA sequencing data from the TCGA and GEO databases, we scrutinized the expression profiles of lactylation‐associated genes and pinpointed a signature comprising eight genes strongly linked to prognosis based on a machine learning integrative framework. Our prognostic model, incorporating the expression levels of these lactylation‐associated genes, demonstrated high accuracy in predicting patient outcomes, including survival rates and response to immunotherapy. Furthermore, functional analyses revealed the potential mechanisms through which lactylation‐associated genes contribute to bladder cancer progression and treatment resistance. Further validation of the close association of these eight genes with bladder cancer was also confirmed through in vitro RT‐PCR experiments and Human Protein Atlas (HPA). The drug enrichment analysis and molecular docking provide us with potential drugs and their binding modes with target proteins. To further investigate the relationship between the model gene and bladder cancer, we conducted a series of in vitro experiments. Results: We found that knockdown of AHNAK reduced the proliferation, migration, and invasion abilities of bladder cancer cells and also promoted cell apoptosis. Discussion: Overall, our study highlights the importance of lactylation‐associated genes as prognostic markers and potential therapeutic targets in bladder cancer. Conclusion: Our identification of this gene signature lays the groundwork for personalized treatment strategies and enhanced patient management in clinical practice.
- 8 January 2026
- Published by Wiley in Cancer Medicine
- Vol. 15 (1) , e71477
Open AccessMachine Learning Integration Framework Constructs a Lactylation‐Associated Gene Signature to Improve Prognosis in Bladder Cancer
Background: Bladder cancer remains a significant challenge in oncology owing to its high recurrence rates and limited treatment options, particularly in cases of resistance to standard therapies. Aims: Our study aimed to pinpoint a lactylation‐associated gene signature capable of predicting prognosis and providing important theoretical support for drug development and precision therapy in bladder cancer patients. Materials and Methods: Leveraging RNA sequencing data from the TCGA and GEO databases, we scrutinized the expression profiles of lactylation‐associated genes and pinpointed a signature comprising eight genes strongly linked to prognosis based on a machine learning integrative framework. Our prognostic model, incorporating the expression levels of these lactylation‐associated genes, demonstrated high accuracy in predicting patient outcomes, including survival rates and response to immunotherapy. Furthermore, functional analyses revealed the potential mechanisms through which lactylation‐associated genes contribute to bladder cancer progression and treatment resistance. Further validation of the close association of these eight genes with bladder cancer was also confirmed through in vitro RT‐PCR experiments and Human Protein Atlas (HPA). The drug enrichment analysis and molecular docking provide us with potential drugs and their binding modes with target proteins. To further investigate the relationship between the model gene and bladder cancer, we conducted a series of in vitro experiments. Results: We found that knockdown of AHNAK reduced the proliferation, migration, and invasion abilities of bladder cancer cells and also promoted cell apoptosis. Discussion: Overall, our study highlights the importance of lactylation‐associated genes as prognostic markers and potential therapeutic targets in bladder cancer. Conclusion: Our identification of this gene signature lays the groundwork for personalized treatment strategies and enhanced patient management in clinical practice.
- Open Access
- 1 January 2023
- Published by FapUNIFESP (SciELO) in Acta Cirurgica Brasileira
- Vol. 38, e382523
Puerarin alleviated oxidative stress and ferroptosis during renal fibrosis induced by ischemia/reperfusion injury via TLR4/Nox4 pathway in rats
To investigate the role of puerarin on renal fibrosis and the underlying mechanism in renal ischemia and reperfusion (I/R) model.
- 1 January 2023
- Published by FapUNIFESP (SciELO) in Acta Cirurgica Brasileira
- Vol. 38, e382523
Open AccessPuerarin alleviated oxidative stress and ferroptosis during renal fibrosis induced by ischemia/reperfusion injury via TLR4/Nox4 pathway in rats
To investigate the role of puerarin on renal fibrosis and the underlying mechanism in renal ischemia and reperfusion (I/R) model.